A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Xisomab 3G3 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 29 May 2017
At a glance
- Drugs Xisomab 3G3 (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Aronora
- 22 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
- 22 May 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
- 22 May 2017 Status changed from not yet recruiting to recruiting.